Relmada Therapeutics Inc (RLMD) Q3 2026 Earnings Call Highlights: Durable 18-Month NDV01 Data, ...
Relmada Therapeutics Inc (RLMD) reported 86% sustained complete responses at 18 months for NDV01, a cash position funding operations through 2029, and plans to file INDs for NDV01 and sepranolone by Related Stocks: RLMD ,